Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
891 Views
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. In this insight, we...
975 Views
China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
568 Views
Shanghai/Shenzhen Connect Ideas: Moutai Inflows Were Back, Tsingtao Too (2019-06-14)
In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...
732 Views
Hansoh Pharma (翰森制药) Post-IPO Trading Update: Fairly Valued
Hansoh Pharma's IPO was priced at the high end and started trading last Friday. In our earlier note, we argued that the company should trade at...
715 Views